Novo Nordisk's U.S. stock pre-market rose over 8%, clinical trials show its weight loss drug Amycretin reduces weight by 22%
I'm PortAI, I can summarize articles.
諾和諾德美股盤前漲超 8%，因其減肥藥 Amycretin 的臨牀試驗結果顯示，患者在 36 周內體重減輕 22%。該公司計劃進一步開發 Amycretin，針對成人超重或肥胖患者。
諾和諾德宣佈了一項針對 Amycretin 的 1b/2a 期臨牀試驗結果。接受 Amycretin 治療的患者在 20 周後體重減輕了 9.7%，28 周後減輕了 16.2%，36 周後減輕了 22.0%。基於這一結果，諾和諾德正計劃進一步開發用於成人超重或肥胖患者的 Amycretin。
風險提示及免責條款
市場有風險，投資需謹慎。本文不構成個人投資建議，也未考慮到個別用户特殊的投資目標、財務狀況或需要。用户應考慮本文中的任何意見、觀點或結論是否符合其特定狀況。據此投資，責任自負。
Source: 華爾街見聞 The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments